Overview
TRANSCENTA-B (6628)
Transcenta Holding Limited, a clinical stage biopharmaceutical company, engages in the discovery, research, development, manufacture, and commercialization of v...
- Open
- 0.650
- High
- 0.660
- Low
- 0.620
- Prev. Close
- 0.665
- Volume
- 165.00K
- Turnover
- 105.91K
- Avg Price
- 0.642
- Bid/Ask Ratio
- 23.08%
- Amplitude
- 6.02%
- 52wk High
- 3.060
- Volume Ratio
- 0.60
- Turnover Ratio
- 0.04%
- 52wk Low
- 0.545
- HK Mkt Cap
- 285.59M
- Market CapHKD
- 285.59M
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -0.410
- EPSDynamic
- -0.342
- EPSStatic
- --
- BVPS
- 1.40
- P/B
- 0.45
- HK Shares
- 453.32M
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 453.32M
- Min lot size
- 500
- Currency
- HKD
TRANSCENTA-B Analyst Rating
View moreForecast & Rating
Oct 16, 2025- Strong buy100.00%
- Buy0.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 1
- Buy
- 0
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Jul, 3
Transcenta staged a recovery after morning weakness, hitting an intraday low of HKD 1.17 before rebounding to close at HKD 1.29, up 2.4% from yesterday's close of HKD 1.26. The rebound was driven by positive clinical data for Ozekibart, which targets a rare cancer treatment gap, and strengthened market confidence following Inhibrx's data supporting an FDA filing. Despite a 26.3% YoY decline in Q4 revenue to HKD 2.63 million, net loss narrowed 37.3% with EPS improving from -HKD 0.206 to -HKD 0.124. The stock remains 77.8% below its 52-week high of HKD 5.80 and trades below both the 20-day MA (HKD 1.35) and 60-day MA (HKD 1.92), with a YTD decline of 42.7%. However, recent share placements raising approximately HKD 59.34 million and grants of 451,500 employee share awards have alleviated liquidity concerns.
